Antitumor drugs are a general term for medications used to treat malignant tumors, control tumor progression, and improve patients' quality of life. They occupy a crucial position in the modern comprehensive cancer treatment system. Through various mechanisms, such as directly killing tumor cells, inhibiting tumor proliferation and metastasis, blocking microenvironmental signals essential for tumor survival, or activating the body's immune response, they provide important supplements and extensions to surgery, radiotherapy, and interventional therapy, significantly enhancing the breadth and depth of cancer treatment.
From the perspective of mechanism of action, antitumor drugs can be divided into several categories. Traditional cytotoxic chemotherapeutic drugs exert their effects by interfering with key stages of the cell division cycle. For example, alkylating agents and platinum compounds can covalently bind to DNA, preventing its replication and transcription; antimetabolites mimic nucleotide structures, incorporating into the synthesis process to inhibit nucleic acid production; plant-derived vinca alkaloids and taxanes act on microtubules, interfering with spindle formation and preventing cancer cell division. These drugs have a broad-spectrum killing effect on rapidly proliferating cells, but they can also affect normally proliferating tissues such as hematopoietic cells and digestive tract mucosa, thus requiring precise control of dosage and treatment duration.
With advancements in molecular biology, targeted therapies have emerged. These drugs target tumor-specific gene mutations, receptor overexpression, or abnormal signaling pathways. For example, tyrosine kinase inhibitors can block signal transduction of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR), inhibiting tumor growth and angiogenesis; monoclonal antibody drugs mediate antibody-dependent cytotoxicity (ADCC) or directly inhibit signal activation by specifically binding to tumor cell surface antigens or ligands. Targeted drugs offer higher selectivity and lower systemic toxicity compared to traditional chemotherapy, but suitable patients need to be selected based on biomarker testing.
Immunotherapy is a major breakthrough in recent years, its core being to relieve the suppression of the body's immune system by tumors or enhance the ability of immune cells to recognize and kill tumors. Immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) can block inhibitory signals between tumor cells and immune cells, restoring T cell attack function; adoptive cell therapies such as chimeric antigen receptor T cells (CAR-T) use genetic engineering to modify the patient's own T cells, enabling them to accurately recognize tumor antigens and efficiently eliminate tumor lesions. Immunotherapy has shown the potential for durable remission in various advanced solid tumors and hematological malignancies, but it also presents challenges in managing immune-related adverse reactions.
The application of anti-tumor drugs emphasizes multidisciplinary collaboration and individualized strategies. Clinicians need to comprehensively consider tumor type, stage, molecular subtyping, patient performance status, and previous treatment history to develop a complete plan that includes drug selection, combination regimens, route of administration, and supportive care. Efficacy assessment relies not only on imaging and changes in tumor markers but also on quality of life and long-term survival benefits.
Currently, anti-tumor drug development is moving towards higher specificity, lower toxicity, and broader indications. The rise of new technologies such as bispecific antibodies, antibody-drug conjugates (ADCs), and protein degradation-targeting chimeric conjugates (PROTACs) offers possibilities for overcoming drug resistance and expanding the boundaries of treatment. Meanwhile, medication prediction models based on big data and artificial intelligence are helping to optimize treatment selection and control adverse reactions.
In conclusion, anti-tumor drugs, as a core weapon in the fight against cancer, have moved from a single-target killing mechanism to a new stage of multi-mechanism, precision, and immune synergy. Their continued development will undoubtedly bring more hope and possibilities for humanity to overcome malignant tumors.